INTRODUCTION
RNA interference (RNAi) has become a powerful tool in reverse genetics. Sustained RNAi can be achieved with the application of short hairpin RNA (shRNA) synthesized by either an RNA polymerase III (pol III) or an RNA polymerase II (pol II) promoter (1) . Pol III promoters have been widely used to synthesize shRNA in culture and in viral vectors. However, they lack temporal and spatial control in vivo, and their successful use in transgenic animals has been limited (2) . This contrasts with a wide array of pol II promoters that confer properties ranging from ubiquitous expression to cell-and time-specific expression in transgenic animals. Pol II is also the endogenous promoter for expression of microRNA (miRNA) (3) (4) (5) and thus may mimic the action of miRNA when it is used to express shRNA in vivo. Furthermore, pol II can express multiple endogenous miRNA genes in the same transcript (5, 6) . In some circumstances, expression of multiple shRNAs that are capable of knocking down multiple genes simultaneously can accelerate investigations of gene interactions. We combined these advantages in a pol II-shRNA system and built an inducible construct that can inducibly express multiple shRNAs and silence expression of multiple genes.
MATERIALS AND METHODS

Plasmid Construction
Constructs that express enhanced green fluorescent protein (EGFP) driven by human ubiquitin C (UbC) promoter have been described previously (7) . For construction of tetracycline-regulatable UbC promoters, the tetracycline-responsive element (TRE) was inserted into two sites: one within the promoter region and the other in the first noncoding exon of the human UbC gene. To insert the TRE in the promoter, a restriction site for XhoI was introduced at a position 5 nucleotides (nt) downstream of the TATA box by changing the sequence 5′-… TATATAAGGACGCGCCGG…-3′ to 5′-…TATATAAGGACGCtCgaG…-3′. To insert the TRE in the first exon, an XhoI site was created at a position 26 nt downstream from the transcription start site by changing the sequence 5 ′ -… G G G T C G C G G T T C T T … -3′ to 5′-…GGGTCtCGagTCTT…-3′. One or two TRE sites (5′-TCC CTATCAGTGATAGAGA-3′) were then inserted at the XhoI site ( Figure  1A ). The insertions destroyed the XhoI sites.
The self-regulatable UbC vector ( Figure 2A ) was built in two steps (1) . The EGFP coding sequence of the UbC-EGFP vector was replaced with the coding sequence for a tetracycline-controlled transcriptional silencer (tTS) that was PCR-cloned from pTeTtTS vector (Clontech Laboratories, Mountain View, CA, USA). Two restriction sites for XhoI and NotI were included in the downstream primer and introduced after the insertion (2). The newly constructed vector (UbC-tTS) was sequentially digested with restriction enzymes XhoI and NotI. The internal ribosome entry site (IRES) of the encephalomyocarditis virus and the EGFP coding region were released from the pIRES2-EGFP vector (Clontech Laboratories) by digestion with XhoI and NotI and then ligated into the UbC-tTS to generate the UbCtTS-IRES-EGFP (Figure 2A) .
The constructs for simultaneous expression of multiple shRNAs were constructed from UbC-TRE4 ( Figure  1 ) in the following steps. The fifth intron of the human actin gene with a 5-nt flanking sequence at each end was chemically synthesized and inserted at the EcoRV site, which is 10 nt from the 3′ end of the first intron of the human ubiquitin C gene. The EcoRV site was destroyed by this insertion. The fourth intron of human actin gene with a 5-nt flanking sequence was chemically synthesized and inserted at the XhoI site (inactivated by insertion) downstream of the EGFP coding region. The individual hairpins were chemically synthesized and inserted sequentially into the EcoRI site within the first intron of the human ubiquitin C gene, the PstI site (introduced during the chemical synthesis) in the fifth intron of the human actin gene, and the XhoI site (also introduced during the chemical synthesis) inside the fourth intron of the human actin gene ( Figure  3A 
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and mouse Dj-1 gene, 5′-GCAGU GUAGCCGUGAUGUAAU-3′.
The target vector was constructed based on the pGL2-luc vector (Promega, Madison, WI, USA), which synthesizes firefly luciferase. Approximately 100 bp downstream from the firefly luciferase opening reading frame (ORF) in the 3′ untranslated region (UTR), synthetic oligonucleotides containing the shRNA target sequences were inserted. All constructs were sequenceverified.
Cell Culture, Transfection, and Induction
Human HEK293 cells and the mouse embryonic NF-1 cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ mL penicillin, and 100 μg/mL streptomycin. Twenty-four hours before transfection, cells (70%-90% confluence) were detached by trypsinization, transferred to 6-well plates, plated at 900,000 cells/well for HEK293 cells or at 400,000 cells/well for NF-1 cells, and cultured in 10% FBS-containing medium without antibiotics. The cells were transfected using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA). The transfection efficiency is >90% in all experiments. The FBS was added back 4 h posttransfection. The growth medium was regularly changed every 24 h.
To induce the expression of the genes (EGFP or shRNA) driven by the tetracycline-regulated UbC promoters, doxycycline was added to the culture medium 4 h posttransfection and was maintained at 1 μg/mL until the cells were harvested.
Dual Fluorescence Assay
The doxycycline-inducible vectors, which express EGFP, and the transfection control vector pDsRed2-N1 (Clontech Laboratories), which encodes red fluorescent protein (RFP), were cotransfected into HEK293 cells cultured in 6-well plates. Each well was transfected with a mixture of 0.5 μg target vector, 1.2 μg pDsRed1-N1 vector, 1 μg pTeT-tTS, and 10 μL Lipofectamine 2000 in 0.5 mL serum- 
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Applied Science, Indianapolis, IN, USA). Cell lysate was cleared by centrifugation at 15,000× g at 4°C for 10 min. The total protein in the supernatant was measured with BCA™ (bicinchoninic acid) Assay kit (Pierce Chemical, Rockville, IL, USA). Concentration of total protein in each sample was adjusted to 0.25 mg/mL with the reporter buffer.
One hundred forty microliters of each sample were measured by fluorescence spectroscopy (Photon Technology International, Birmingham, NJ, USA). Fluorescence of GFP in cell lysates was detected by exciting at 460 nm and recording from 480-600 nm; the spectrum peak at 508 nm represents the fluorescence intensity of GFP. Fluorescence of RFP in the same cell lysates was detected by exciting at 530 nm and recording from 560-650 nm; the spectrum peak at 580 nm represents the fluorescence intensity of RFP. The fluorescence intensity ratio of target (GFP) to control (RFP) was determined and normalized to that transfected with the control vector UbC-target-EGFP in the absence of doxycycline.
Luciferase Assay
HEK293 cells were cultured in 24-well plates and transfected with a mixture of 0.25 μg of either shRNA-expressing vector or the empty carrier vector, 0.25 µg firefly luciferase (Pp-luc) vector with the respective shRNA target sequence inserted in the 3′ UTR (pGL2-luc-sod1), 0.15 μg renilla luciferase (Rr-luc)-expressing vector pRL-TK as transfection control, and 0.3 μg pTeT-tTS, which expresses the tetracycline-controlled transcriptional silencer (tTS). The cells were harvested at 28 h posttransfection. The luciferase activity in the cleared cell lysate was measured with the DualLuciferase ® Assay kit (Promega) using a PhL™ Luminometer (Mediators Diagnostika, Vienna, Austria). The luciferase activity was expressed as the ratio of Pp-luc activity to Rr-luc activity. This ratio was further normalized to the control, which was transfected with the Pp-luc, Rr-luc, and the empty UbC carrier vector in the absence of doxycycline.
Immunoblots
NF-1 cells were transfected in 6-well plates and were harvested at 30 h posttransfection. The cell pellets were lysed in an ice-cold lysis buffer containing 0.4% Nonidet™ P40 (NP40), 0.2 mM Na 3 VO 4 , 20 mM Hepes, pH 7.9, and a cocktail of protease inhibitors (Complete-Mini; Sigma, St. Louis, MO, USA). The total protein, in the cleared lysate, was determined with the BCA Assay kit (8) . Forty micrograms total proteins were resolved on a 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel and blotted onto GeneScreen Plus ® membrane (PerkinElmer Life and Analytical Sciences, Wellesley, MA, USA). The immunoreactive signal for each protein was detected using specific primary antibodies and SuperSignal™ kit (Pierce Chemical) and documented by using the Kodak Digital Image Station 440CF (Eastman Kodak, Rochester, NY, USA). The primary antibodies were: sheep anti-superoxide dismutase-1 (SOD1, 1:1000; BioDesign 
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International, Saco, ME, USA), rabbit anti-Mn superoxide dismutase (SOD2, 1:1000; Stressgen Biotechnologies, San Diego, CA, USA), goat anti-DJ1 (1:500; Abcam, Cambridge, UK), and mouse anti-glyceraldehye-3-phosphate dehydrogenase (GAPDH; 1:10,000; Abcam).
RESULTS AND DISCUSSION
Human UbC promoter is a ubiquitous promoter that works well in transgenic animals (9) (10) (11) . Therefore, we modified it so that it can be regulated. We inserted one or two TRE into the promoter or into the first noncoding exon of our UbC-EGFP construct ( Figure 1A ) and tested whether these modifications rendered the UbC promoter regulatable by doxycycline ( Figure 1B ). After cotransfection with the pTeT-tTS vector, which expresses a TRE binding repressor tTS, we observed that all four modifications produced doxycycline-dependent expression of EGFP ( Figure 1B) . Because the four modified constructs are regulatable to the same degree, we choose the constructs with the TRE elements inserted in the first exon for further experiments.
We first built a self-regulated construct to express a pol II transcript (Figure 2A ) (see the Materials and Methods section). In this construct, the UbC promoter synthesizes a transcript that contains sequentially tTS ORF, IRES, and EGFP ORF. Because UbC drives the expression of tTS, we expected that the expression level of EGFP would be low in the absence of doxycycline for the construct UbC-TRE-tTS-IRES-EGFP, which has a TRE in the first exon. By addition of doxycycline, the expression would be induced. For the construct UbCtTS-IRES-EGFP, which does not have TRE, we expected that it would not be regulated by doxycycline. These expectations were confirmed by our experiments ( Figure 2B ). EGFP expression was low in the absence of doxycycline and was dose-dependently induced by addition of doxycycline for the UbC-TRE-tTS-IRES-EGFP construct ( Figure 2B ), while EGFP expression was high and was not dependent on doxycycline induction for the UbCtTS-IRES-EGFP construct ( Figure  2B ).
To determine whether the UbC-TRE-tTS-IRES-EGFP construct can express an shRNA and mediate doxycycline-regulatable knockdown of the endogenous cellular target gene, we inserted a hairpin that encodes an shRNA against the mouse Sod2 gene (Figure 2A, construct 3) and transfected the plasmid into mouse NF-1 cells. Thirty hours after the transfection, Western blot analysis demonstrated that endogenous Sod2 gene expression was silenced ( Figure 2C ). This result demonstrates that the self-regulation strategy can be used to effectively and regulatably silence an endogenous cellular gene.
To build a construct that can express multiple shRNAs, we combined multiple exons and introns in a vector based on the regulatable pol II construct ( Figure 3A ) (see the Materials and Methods section) and inserted one hairpin in each intron. The hairpins were designed to mimic human miR-30, a folding structure based on our previous work (7); they target human sod1, mouse Sod2, or mouse Dj-1 gene, respectively ( Figure 3A, construct 5) . As a basis of comparison, we also built a set of three constructs in which each member has only one shRNA-encoding hairpin directed against one of the three target genes. These individual shRNA-expressing plasmids ( Figure  3A , constructs 2-4) all had the hairpin placed in the first intron. Each construct was tested by cotransfecting it into HEK293 cells with a tTS-expression plasmid and the individual Luc-target constructs (Figure 3, B-D) . In a doxycycline-dependent manner, the constructs that carry one hairpin (constructs 2-4) silenced their specific target, and the construct that carries hairpins against all three targets (construct 5) silenced all three targets (Figure 3, B-D) . The degree of silencing is comparable between the single and multiple hairpin constructs.
To further determine whether construct 5 can silence the three targets simultaneously in the same cells, we cotransfected construct 5 with a human SOD1-expressing plasmid into the mouse NF-1 cells. We detected the transfected human SOD1 and the endogenous mouse SOD2 and DJ-1 proteins by immunoblots. We found that all three proteins were significantly knocked down. Based on these results, we conclude that pol II transcripts carrying multiple hairpins can be used to silence multiple genes simultaneously.
This multi-silencing construct can be used in investigations where knockdown of multiple genes is required. It can be used to investigate whether genes are in sequential or parallel pathways and whether genes are performing redundant roles and acting synergistically or antagonistically. This multiple knockdown strategy can also be used in transgenic mice. Compared with the gene knockout approach, this multiple knockdown approach can avoid having to carry out multiple crosses of individual knockout lines and, therefore, can accelerate investigations of gene-gene interactions in vivo.
